Professor David Eyre
- AI-based smart hospitals: developing, deploying and evaluating tools to help hospitals manage demand
- Dynamic Time-to-Event Analysis for Infection Treatment in Hospitals
- Infectious Disease Epidemiology Unit
- Machine learning for treating infections in hospital
- Pathogen population genomics methods and applications
- Using machine learning and statistical prediction models to improve empirical antibiotic prescribing
- Robertson Fellow
- Infectious Diseases Clinician
My research interests include the use of whole-genome sequencing as a tool for understanding the epidemiology and transmission of bacterial and fungal pathogens. My previous work has described the transmission of the major healthcare-associated pathogen Clostridium difficile and has also included large-scale sequencing projects tracking the spread of gonorrhoea and the emerging multi-drug resistant fungus Candida auris. I am currently working on developing mathematical models for pathogen transmission that allow risk factors for transmission to be identified, as a means to suggest potential interventions to prevent infections spreading.
I am also interested in using sequencing technologies as a novel tool for culture-independent microbiology diagnostics. These technologies offer the prospect of same-day diagnosis of infection, rather than having to wait several days for bacteria to grow in the lab. I have developed methods using sequencing data to detect the presence of infection, e.g. from orthopedic devices removed from patients, as well as predict antibiotic resistance, e.g. in Enterobacteriaceae and Neisseria gonorrhoeae.
Additionally I work on using routinely collected healthcare data to investigate the epidemiology of infectious diseases and to investigate individual patient responses to infection and treatment.
I work closely with the Modernising Medical Microbiology consortium on several of these projects.
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease.
Wellens J. et al, (2022), Gut, 71, 1919 - 1922
Time-of-Day Variation in SARS-CoV-2 RNA Levels during the Second Wave of COVID-19.
Zhuang X. et al, (2022), Viruses, 14
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
Wei J. et al, (2022), Nat Commun, 13
Assessment of an institutional guideline for vancomycin dosing and identification of predictive factors associated with dose and drug trough levels
Qingze G. et al, (2022), Journal of Infection
Chest CT and Hospital Outcomes in Patients with Omicron Compared with Delta Variant SARS-CoV-2 Infection.
Tsakok MT. et al, (2022), Radiology